论文部分内容阅读
对高胆固醇血症的药物治疗仍有争议,主要是因为缺乏提高生存率的临床实验依据。本试验对患冠心病患者用Simvastatin治疗,以评价降低胆固醇对冠脉事件发生率及死亡率的作用。 4444例有心绞痛或陈旧性心肌梗塞史的病人,血清胆固醇浓度在5.5～8.0mmol/L之间,在低脂饮食下用Simvastatin或安慰剂进行随机双盲治疗。平均随访时间不少于5.4年,Simvastatin使总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇平均改变
Drug treatment of hypercholesterolemia is still controversial, mainly because of the lack of clinical trials to improve survival rates. In this study, patients with coronary heart disease were treated with Simvastatin to evaluate the effect of lowering cholesterol on the incidence of coronary events and mortality. Of 4444 patients with a history of angina or old myocardial infarction, serum cholesterol concentrations ranged from 5.5 to 8.0 mmol / L and were randomized to double-blind treatment with Simvastatin or placebo in a low-fat diet. With an average follow-up of no less than 5.4 years, Simvastatin averaged changes in total cholesterol, low density lipoprotein cholesterol, and high-density lipoprotein cholesterol